nach oben

Die Gynäkologie

Erschienen in:

25.10.2016 | Polyzystisches Ovarialsyndrom | Leitthema

Risk factors in adolescence for the development of polycystic ovary syndrome

verfasst von: Laure Morin-Papunen, M.D., Associate Professor

Erschienen in: Die Gynäkologie | Ausgabe 11/2016

Einloggen, um Zugang zu erhalten

Abstract

Background

Polycystic ovary syndrome (PCOS) is the most common gynaecological endocrinopathy in women of fertile age and represents a major health issue among women affecting not only reproductive function, but also emergence of the most frequent causes of morbidity and mortality in women of postmenopausal age – type 2 diabetes mellitus (T2DM) and cardiovascular diseases (CVDs). The current epidemic of obesity suggests that the prevalence of PCOS and its adverse health effects may rise even further in the future.

Objectives

The ability to predict development of PCOS early in life would be essential to decrease and prevent late morbidity linked to PCOS, although, on the other hand, over-diagnosis should be avoided as it can lead to unnecessary labelling and can impact on an adolescent’s quality of life.

Materials and methods

Systematic search in the Medline literature database through PubMed using the search terms “Polycystic ovary syndrome”, “PCOS”, “Adolescents”, “Polycystic ovary morphology”, “PCOM”, “Menstrual disorders in adolescence”, “Hirsutism”, “Hyperandrogenaemia”, “Anti-Müllerian hormone”, “Obesity and adolescents” and “Prediction of PCOS”.

Results and conclusions

Follow-up and re-evaluation are warranted in all adolescents with features suggestive of PCOS, such as menstrual irregularities two or more years after menarche, or a menstrual interval >90 days, moderate to severe hirsutism and moderate to severe inflammatory acne vulgaris unresponsive to topical medication. Because of the strong association between obesity, weight gain through life, hyperandrogenism and development of PCOS, screening for PCOS and overweight/obesity as early as in adolescence is important in order to tailor treatment and intervention protocols and reduce future risks of infertility, CVDs and T2DM.

Adams J, Polson DW, Franks S (1986) Prevalence of polycystic ovaries in women with anovulation and idiopathic hirsutism. Br Med J (Clin Res Ed) 293:355–359CrossRef

Apter D, Vihko R (1990) Endocrine determinants of fertility: serum androgen concentrations during follow-up of adolescents into the third decade of life. J Clin Endocrinol Metab 71:970–974CrossRefPubMed

Apter D, Vihko R (1977) Serum pregnenolone, progesterone, 17-hydroxyprogesterone, testosterone and 5 alpha-dihydrotestosterone during female puberty. J Clin Endocrinol Metab 45:1039–1048CrossRefPubMed

Azziz R et al (2004) Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab 89:453–462CrossRefPubMed

Bhagavath B et al (2014) Metformin and other insulin sensitizers in polycystic ovary syndrome. Semin Reprod Med 32:323–330CrossRefPubMed

Blank SK et al (2008) Polycystic ovary syndrome in adolescence. Ann N Y Acad Sci 1135:76–84CrossRefPubMed

Bridger T et al (2006) Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 160:241–246CrossRefPubMed

Carmina E, Oberfield SE, Lobo RA (2010) The diagnosis of polycystic ovary syndrome in adolescents. Am J Obstet Gynecol 203:201.e1–201.e5CrossRef

Carmina E et al (2006) Extensive clinical experience: relative prevalence of different androgen excess disorders in 950 women referred because of clinical hyperandrogenism. J Clin Endocrinol Metab 91:2–6CrossRefPubMed

10.

Carroll J, Saxena R, Welt CK (2012) Environmental and genetic factors influence age at menarche in women with polycystic ovary syndrome. J Pediatr Endocrinol Metab 25:459–466CrossRefPubMedPubMedCentral

11.

Chung PW et al (2011) Menstrual disorders in a paediatric and adolescent gynaecology clinic: patient presentations and longitudinal outcomes. Hong Kong Med J 17:391–397PubMed

12.

Codner E et al (2011) Elevated anti-Mullerian hormone (AMH) and inhibin B levels in prepubertal girls with type 1 diabetes mellitus. Clin Endocrinol (Oxf) 74:73–78CrossRef

13.

Coviello AD, Legro RS, Dunaif A (2006) Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab 91:492–497CrossRefPubMed

14.

Dewailly D et al (2014) Definition and significance of polycystic ovarian morphology: a task force report from the Androgen Excess and Polycystic Ovary Syndrome Society. Hum Reprod Update 20:334–352CrossRefPubMed

15.

Dewailly D et al (2011) Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on ultrasound and of the serum AMH level for the definition of polycystic ovaries. Hum Reprod 26:3123–3129CrossRefPubMed

16.

Diamanti-Kandarakis E, Panidis D (2007) Unravelling the phenotypic map of polycystic ovary syndrome (PCOS): a prospective study of 634 women with PCOS. Clin Endocrinol (Oxf) 67:735–742CrossRef

17.

Dramusic V et al (1997) Clinical, endocrinologic, and ultrasonographic features of polycystic ovary syndrome in Singaporean adolescents. J Pediatr Adolesc Gynecol 10:125–132CrossRefPubMed

18.

Ferriman D, Gallway JD (1961) Clinical assessment of body hair growth in women. J Clin Endocrinol Metab 21:1440–1447CrossRefPubMed

19.

Franks S (2015) Can animal models of PCOS help point the way towards early and effective therapeutic intervention in women with the syndrome? Endocrinology 156:2371–2373CrossRefPubMed

20.

Fraser IS, Kovacs G (2004) Current recommendations for the diagnostic evaluation and follow-up of patients presenting with symptomatic polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 18:813–823CrossRefPubMed

21.

Geier LM, Bekx MT, Connor EL (2012) Factors contributing to initial weight loss among adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 25:367–370CrossRefPubMed

22.

Glintborg D et al (2012) Age associated differences in prevalence of individual rotterdam criteria and metabolic risk factors during reproductive age in 446 caucasian women with polycystic ovary syndrome. Horm Metab Res 44:694–698CrossRefPubMed

23.

Glintborg D et al (2015) Morbidity and medicine prescriptions in a nationwide Danish population of patients diagnosed with polycystic ovary syndrome. Eur J Endocrinol 172:627–638CrossRefPubMed

24.

Handelsman DJ, Wartofsky L (2013) Requirement for mass spectrometry sex steroid assays in the Journal of Clinical Endocrinology and Metabolism. J Clin Endocrinol Metab 98:3971–3973CrossRefPubMed

25.

Hart R et al (2011) Extent of metabolic risk in adolescent girls with features of polycystic ovary syndrome. Fertil Steril 95:2347–2353.e1CrossRefPubMed

26.

Hoeger KM, Oberfield SE (2012) Do women with PCOS have a unique predisposition to obesity? Fertil Steril 97:13–17CrossRefPubMed

27.

Ibanez L et al (2011) Early metformin therapy (age 8–12 years) in girls with precocious pubarche to reduce hirsutism, androgen excess, and oligomenorrhea in adolescence. J Clin Endocrinol Metab 96:E1262–E1267CrossRefPubMed

28.

Ibanez L et al (2001) Sensitization to insulin induces ovulation in nonobese adolescents with anovulatory hyperandrogenism. J Clin Endocrinol Metab 86:3595–3598CrossRefPubMed

29.

Ibanez L et al (2011) Treatment of androgen excess in adolescent girls: ethinylestradiol-cyproteroneacetate versus low-dose pioglitazone-flutamide-metformin. J Clin Endocrinol Metab 96:3361–3366CrossRefPubMed

30.

Johnstone EB et al (2012) Age-related differences in the reproductive and metabolic implications of polycystic ovarian syndrome: findings in an obese, United States population. Gynecol Endocrinol 28:819–822CrossRefPubMed

31.

Johnstone EB et al (2010) The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab 95:4965–4972CrossRefPubMedPubMedCentral

32.

Kajaia N et al (2007) Low sex hormone-binding globulin as a predictive marker for insulin resistance in women with hyperandrogenic syndrome. Eur J Endocrinol 157:499–507CrossRefPubMed

33.

La Marca A et al (2009) Anti-Mullerian hormone (AMH): what do we still need to know? Hum Reprod 24:2264–2275CrossRefPubMed

34.

Legro RS et al (2013) Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 98:4565–4592CrossRefPubMed

35.

Legro RS (2012) Obesity and PCOS: implications for diagnosis and treatment. Semin Reprod Med 30:496–506CrossRefPubMedPubMedCentral

36.

Lewy VD et al (2001) Early metabolic abnormalities in adolescent girls with polycystic ovarian syndrome. J Pediatr 138:38–44CrossRefPubMed

37.

March WA et al (2010) The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod 25:544–551CrossRefPubMed

38.

Mortensen M et al (2009) Asymptomatic volunteers with a polycystic ovary are a functionally distinct but heterogeneous population. J Clin Endocrinol Metab 94:1579–1586CrossRefPubMedPubMedCentral

39.

Nduwayo L et al (1992) Primary amenorrhea revealing micropolycystic ovary syndrome. Presse Med 21:1060–1063PubMed

40.

Ollila MM et al (2016) Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome: prospective cohort study. J Clin Endocrinol Metab 101:739–747CrossRefPubMed

41.

Ornstein RM, Copperman NM, Jacobson MS (2011) Effect of weight loss on menstrual function in adolescents with polycystic ovary syndrome. J Pediatr Adolesc Gynecol 24:161–165CrossRefPubMed

42.

Panidis D et al (2013) Association between menstrual cycle irregularities and endocrine and metabolic characteristics of the polycystic ovary syndrome. Eur J Endocrinol 168:145–152CrossRefPubMed

43.

Pawelczak M et al (2012) Elevated serum anti-Mullerian hormone in adolescents with polycystic ovary syndrome: relationship to ultrasound features. J Pediatr Endocrinol Metab 25:983–989CrossRefPubMedPubMedCentral

44.

Pigny P et al (2003) Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest. J Clin Endocrinol Metab 88:5957–5962CrossRefPubMed

45.

Pigny P et al (2006) Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome. J Clin Endocrinol Metab 91:941–945CrossRefPubMed

46.

Piltonen T et al (2005) Serum anti-Mullerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome. Hum Reprod 20:1820–1826CrossRefPubMed

47.

Pinola P et al (2014) Anti-Mullerian hormone: correlation with testosterone and oligo- or amenorrhoea in female adolescence in a population-based cohort study. Hum Reprod 29:2317–2325CrossRefPubMedPubMedCentral

48.

Pinola P et al (2012) Menstrual disorders in adolescence: a marker for hyperandrogenaemia and increased metabolic risks in later life? Finnish general population-based birth cohort study. Hum Reprod 27:3279–3286CrossRefPubMed

48.

Pinola P (2016) Hyperandrogenism, Menstrual Irregularities and Polycystic Ovary Syndrome. Acta Universitatis Ouluensis. Disseration. University of Oulu, Oulu

49.

Polson DW et al (1988) Polycystic ovaries – a common finding in normal women. Lancet 1:870–872CrossRefPubMed

50.

Puurunen J et al (2011) Unfavorable hormonal, metabolic, and inflammatory alterations persist after menopause in women with PCOS. J Clin Endocrinol Metab 96:1827–1834CrossRefPubMed

51.

Rachmiel M et al (2008) Primary amenorrhea as a manifestation of polycystic ovarian syndrome in adolescents: a unique subgroup? Arch Pediatr Adolesc Med 162:521–525CrossRefPubMed

52.

Rosenfield RL (2013) Clinical review: Adolescent anovulation: maturational mechanisms and implications. J Clin Endocrinol Metab 98:3572–3583CrossRefPubMedPubMedCentral

53.

Rosenfield RL (2015) The diagnosis of polycystic ovary syndrome in adolescents. Pediatrics 136:1154–1165CrossRefPubMed

54.

Rosenfield RL, Lipton RB, Drum ML (2009) Thelarche, pubarche, and menarche attainment in children with normal and elevated body mass index. Pediatrics 123:84–88CrossRefPubMed

55.

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004) Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41–47CrossRef

56.

Sadat Hosseini M, Ramezani Tehrani F, Azizi F (2013) The lack of association between idiopathic hirsutism and metabolic disturbances: Iranian PCOS Prevalence Study. Gynecol Endocrinol 29:821–825CrossRefPubMed

57.

Shea JL, Wongt PY, Chen Y (2014) Free testosterone: clinical utility and important analytical aspects of measurement. Adv Clin Chem 63:59–84CrossRefPubMed

58.

Sopher AB et al (2014) Anti-Mullerian hormone may be a useful adjunct in the diagnosis of polycystic ovary syndrome in nonobese adolescents. J Pediatr Endocrinol Metab 27:1175–1179PubMedPubMedCentral

59.

Stubbs SA et al (2005) Anti-mullerian hormone protein expression is reduced during the initial stages of follicle development in human polycystic ovaries. J Clin Endocrinol Metab 90:5536–5543CrossRefPubMed

60.

Venturoli S et al (1995) Longitudinal change of sonographic ovarian aspects and endocrine parameters in irregular cycles of adolescence. Pediatr Res 38:974–980CrossRefPubMed

61.

Wallace IR et al (2013) Sex hormone binding globulin and insulin resistance. Clin Endocrinol (Oxf) 78:321–329CrossRef

62.

Weenen C et al (2004) Anti-Mullerian hormone expression pattern in the human ovary: potential implications for initial and cyclic follicle recruitment. Mol Hum Reprod 10:77–83CrossRefPubMed

63.

Welt CK, Carmina E (2013) Clinical review: Lifecycle of polycystic ovary syndrome (PCOS): from in utero to menopause. J Clin Endocrinol Metab 98:4629–4638CrossRefPubMedPubMedCentral

64.

West S et al (2014) Irregular menstruation and hyperandrogenaemia in adolescence are associated with polycystic ovary syndrome and infertility in later life: Northern Finland Birth Cohort 1986 study. Hum Reprod 29:2339–2351CrossRefPubMedPubMedCentral

65.

Wiksten-Almstromer M, Hirschberg AL, Hagenfeldt K (2008) Prospective follow-up of menstrual disorders in adolescence and prognostic factors. Acta Obstet Gynecol Scand 87:1162–1168CrossRefPubMed

66.

Witchel SF et al (2015) The diagnosis of Polycystic ovary syndrome during adolescence. Horm Res Paediatr 83:376–389CrossRef

67.

Yildiz BO (2006) Diagnosis of hyperandrogenism: clinical criteria. Best Pract Res Clin Endocrinol Metab 20:167–176CrossRefPubMed

68.

van Hooff MH et al (2000) Insulin, androgen, and gonadotropin concentrations, body mass index, and waist to hip ratio in the first years after menarche in girls with regular menstrual cycles, irregular menstrual cycles, or oligomenorrhea. J Clin Endocrinol Metab 85:1394–1400PubMed

69.

van Hooff MH et al (2000) Polycystic ovaries in adolescents and the relationship with menstrual cycle patterns, luteinizing hormone, androgens, and insulin. Fertil Steril 74:49–58CrossRefPubMed

70.

van Hooff MH et al (2004) Predictive value of menstrual cycle pattern, body mass index, hormone levels and polycystic ovaries at age 15 years for oligo-amenorrhoea at age 18 years. Hum Reprod 19:383–392CrossRefPubMed

Titel: Risk factors in adolescence for the development of polycystic ovary syndrome
verfasst von: Laure Morin-Papunen, M.D., Associate Professor
Publikationsdatum: 25.10.2016
Verlag: Springer Medizin
Schlagwörter: Polyzystisches Ovarialsyndrom
Pädiatrische Endokrinologie und Diabetologie
Adipositas
Gynäkologie in der Hausarztpraxis
Endokrinologische Erkrankungen in der Hausarztpraxis
Polyzystisches Ovarialsyndrom
Erschienen in: Die Gynäkologie / Ausgabe 11/2016
Print ISSN: 2731-7102
Elektronische ISSN: 2731-7110
DOI: https://doi.org/10.1007/s00129-016-3935-9

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

19.04.2024 | Vorhofflimmern | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Risk factors in adolescence for the development of polycystic ovary syndrome

Abstract

Background

Objectives

Materials and methods

Results and conclusions

Das könnte Sie auch interessieren

Das polyzystische Ovarsyndrom im Jugendalter

Diagnose PCOS – was bedeutet das für die Betroffene?

Androgenisierung der älteren Patientin

Androgenkonzentrationen und kardiovaskuläre Risiken bei der Frau

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Objectives

Materials and methods

Results and conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2016

Risiken der Anwendung von Koagulationsgeräten im kleinen Becken

CME: Fehlbildungen des weiblichen Genitale

Magazin

Das PCO-Syndrom in verschiedenen Lebensphasen

Umbilikale Läsionen in der Gynäkologie

Theodor Langhans (1839–1915)

Das könnte Sie auch interessieren

Das polyzystische Ovarsyndrom im Jugendalter

Diagnose PCOS – was bedeutet das für die Betroffene?

Androgenisierung der älteren Patientin

Androgenkonzentrationen und kardiovaskuläre Risiken bei der Frau

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Parodontalbehandlung verbessert Prognose bei Katheterablation

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Update Innere Medizin